If the original 24 ‘key customers’ can be convinced to switch to a cheaper - identically effective - BlastX-like product that is streets ahead of whatever they have been using in the meantime why would they not do that ?
...But ideally NXS wants 3M to use its power to work for Next Science not against it so just the threat of the Surgx option (if SurgX really can be used in identical situations plus sterile ones too) might be enough to get 3M to be more proactive in regards its selling?
cheers
Ann: Next Science granted its first acne-related patent, page-24
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.88M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.5¢ | 27.0¢ | $28.64K | 104.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 67356 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 3500 | 2 |
View Market Depth
| Last trade - 12.23pm 29/07/2024 (20 minute delay) ? |
| NXS (ASX) Chart |